Clinical trial
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic…
NCT00452140 · Neovii Biotech, Industry · Terminated
Key facts
| NCT number | NCT00452140 |
|---|---|
| Title | Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment |
| Official title | Phase II Study for Repeated Dosing of the Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab in Patients With HER-2/Neu 1+ or 2+/FISH Negative Expressing Advanced or Metastatic Breast Cancer (Stage IIIb/IV) Progressing After Endocrine Treatment |
| Lead sponsor | Neovii Biotech, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer, Advanced Breast Cancer |
| Intervention type | Biological |
| Interventions | ertumaxomab |
| Enrollment | 40 |
| Start date | Mar 1, 2007 |
| Completion | Feb 1, 2009 |
| First posted | Mar 27, 2007 |
| Last update posted | May 19, 2009 |
| Countries | Austria, France, Germany, Italy, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: